Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03289897
Other study ID # PJM124
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 5, 2017
Est. completion date December 31, 2020

Study information

Verified date August 2023
Source Perspectum
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A multi-centre randomised controlled trial to determine the implementation and health care cost of LiverMultiScan vs. routine methodical assessment (standard care) of Non-alcoholic fatty liver disease (NAFLD) across several European countries.


Description:

Non-alcoholic fatty liver disease (NAFLD) is a condition associated with obesity, insulin resistance and heart disease. Research has shown that fatty liver (steatosis) can lead to a spectrum of diseases including low grade inflammation (steatohepatitis or non-alcoholic steatohepatitis (NASH)), cirrhosis or liver failure. The current method used to diagnose liver dysfunction and failure is with percutaneous liver biopsy. This is painful and is not without risk, as the liver is a highly vascular organ. Even with ultrasound guidance, it carries a 1:1000 risk of serious adverse events (e.g. bleeding, infection, bowel perforation). As a result of these factors, liver biopsy is not used in all patients with suspected NAFLD/ NASH unless moderate to severe liver disease is presented or other liver disease need to be excluded. Various diagnostic pathways have arisen, but in the absence of a clearly non-invasive discriminatory test that can stratify normal liver, simple steatosis, steatohepatitis and cirrhosis, there is no standardised pathway. LiverMultiScan has been tested against liver biopsy and has been shown to be the first imaging test that can identify early liver disease and predict clinical outcomes accurately. LiverMultiScan has recently been CE-Marked and FDA-cleared, so is available for clinical use, but as a new test, it is not yet widely established in clinical practice. This study will utilise LiverMultiScan and see if it can be the basis of a viable diagnostic pathway in EU healthcare systems by adopting it in different EU countries, and determining the economic costs and benefits.


Recruitment information / eligibility

Status Completed
Enrollment 801
Est. completion date December 31, 2020
Est. primary completion date December 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Male and female patients aged 18-75 years, due to undergo evaluation for suspected non-alcoholic fatty liver disease - Presence of: - elevated liver function tests (ALT, AST or GGT = 1.5 x upper limit of normal and = 5 x upper limit of normal) OR - imaging suggestive of Fatty liver disease. OR Presence of = 3 of the following criteria: 1. insulin resistance or type 2 diabetes mellitus 2. obesity (BMI > 30 or waist-to-hip ratio > 1.00 for men / > 0.85 for women) 3. hypertension (= 130/85 mmHg) 4. elevated triglycerides (= 1.7 mmol/l) 5. low HDL-cholesterol (< 1.05 mmol/l for men / < 1.25 mmol/l for women) - Participant is willing and able to give informed consent for participation in the study. Exclusion Criteria: - The participant may not enter the study if they have any contraindication to magnetic resonance imaging (inc pregnancy, extensive tattoos, pacemaker, shrapnel injury, severe claustrophobia). - Patients with proven liver disease other than NAFLD. - Liver transplantation - Patients that present with clinical signs of chronic liver failure (variceal bleeding, ascites, overt encephalopathy) - Pregnancy - Alcohol over-use/ abuse as determined by local guidelines - Patient with known malignant liver tumours and those with any malignancy with life expectancy < 36 months - Heart failure NYHA stages II-IV - Severe mental illness - Any other cause, including a significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
LiverMultiScan
LiverMultiScan is an imaging technique which is able to identify early liver disease.

Locations

Country Name City State
Germany University Hospital Ulm Ulm Baden-Württemberg
Netherlands Leiden University Medical Center Leiden South Holland
Portugal University of Coimbra Coimbra Centro
United Kingdom Ninewells Hospital Dundee
United Kingdom Royal Infirmary of Edinburgh Edinburgh
United Kingdom Glasgow Royal Infirmary Glasgow
United Kingdom Queen Elizabeth University Hospital Glasgow
United Kingdom Aintree Hospital Liverpool Merseyside
United Kingdom King's College Hospital London
United Kingdom St George's Hospital London
United Kingdom Southampton University Hospital Southampton Hampshire

Sponsors (12)

Lead Sponsor Collaborator
Perspectum Glasgow Royal Infirmary, King's College Hospital NHS Trust, Leiden University Medical Center, Liverpool University Hospitals NHS Foundation Trust, NHS Greater Glasgow and Clyde, Ninewells Hospital, Royal Infirmary of Edinburgh, St George's University Hospitals NHS Foundation Trust, University Hospital Southampton NHS Foundation Trust, University Hospital Ulm, University of Coimbra

Countries where clinical trial is conducted

Germany,  Netherlands,  Portugal,  United Kingdom, 

References & Publications (2)

Banerjee R, Pavlides M, Tunnicliffe EM, Piechnik SK, Sarania N, Philips R, Collier JD, Booth JC, Schneider JE, Wang LM, Delaney DW, Fleming KA, Robson MD, Barnes E, Neubauer S. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol. 2014 Jan;60(1):69-77. doi: 10.1016/j.jhep.2013.09.002. Epub 2013 Sep 12. — View Citation

Pavlides M, Banerjee R, Sellwood J, Kelly CJ, Robson MD, Booth JC, Collier J, Neubauer S, Barnes E. Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol. 2016 Feb;64(2):308-315. doi: 10.1016/j.jhep.2015.10.009. Epub 2015 Nov 10. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary To investigate whether the introduction of LiverMultiScan as a standardised diagnostic test for liver disease can prove a cost-effective method in different EU territories. Proportion of patients with suspected NAFLD incurring liver related hospital consultations and/or liver biopsies, from the date of randomisation to the end of the study follow-up. 1 year
Secondary Patient satisfaction: questionnaire Patient feedback from patient satisfaction questionnaire, at baseline, and all follow-up visits to the end of the study. 1 year
Secondary Certainty of diagnosis Certainty of diagnosis is defined as binary (yes/no vs. unlikely/probable) at baseline and all follow-up visits to the end of the study. 1 year
Secondary Frequency of diagnosis Frequency of diagnosis is defined as binary (yes/probable vs. no/unlikely) at baseline and all follow-up visits to the end of the study. 1 year
Secondary Time to diagnosis Time from randomisation to diagnosis by the physician, as recorded at final follow-up visit. 1 year
Secondary Measure resource use Rates of liver related outpatient investigations/consultations/hospital admissions per 400 patients during the study. 1 year
Secondary Cost effectiveness of LiverMultiScan Cost of LiverMultiScan based on randomised comparison. 1 year
Secondary Personnel skills required for diagnosis Percentage of total consultations performed by a specialist, at each specialist medical category, from date of randomisation to end of study. 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT04635202 - Effect of Elliptical Training on Metabolic Homeostasis in Metabolic Syndrome N/A
Completed NCT05343858 - Pilot Study to Evaluate the Effect of Two Microalgae Consumption on Metabolic Syndrome N/A
Completed NCT04053686 - An Intervention to Reduce Prolonged Sitting in Police Staff N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Recruiting NCT05040958 - Carotid Atherosclerotic Plaque Load and Neck Circumference
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05956886 - Sleep Chatbot Intervention for Emerging Black/African American Adults N/A
Completed NCT06057896 - Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
Active, not recruiting NCT03613740 - Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion Phase 2
Completed NCT04498455 - Study of a Prebiotic Supplement to Mitigate Excessive Weight Gain Among Physicians in Residency Phase 4
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT03697382 - Effect of Daily Steps on Fat Metabolism N/A
Completed NCT03241121 - Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome N/A
Completed NCT04509206 - Virtual Teaching Kitchen N/A
Completed NCT05124847 - TREating Pediatric Obesity N/A
Completed NCT03929198 - Translation of Pritikin Program to the Community N/A